Lamont et al. also suggest focussing on the development of a vaccine to tackle these complex pathological processes in pregnancies at risk of adverse outcomes.1Unfortunately, such a vaccine is not yet available, and the issues concerning IAP will also be present in vaccine implementation, e.g. the selection of a population and timing of prophylaxis/immunisation.4